# Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg

> **NCT00751036** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 94 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** Nilotinib
- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT00751036
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-06
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2014-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00751036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00751036, "Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00751036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*